The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.
From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors
Abstract
Members of the B cell lymphoma 2 (BCL-2) gene family have a central role in regulating programmed cell death by controlling pro-apoptotic and anti-apoptotic intracellular signals. In cancer, apoptosis evasion through dysregulation of specific BCL-2 family genes is a recurring event; accordingly, selective inhibition of specific anti-apoptotic BCL-2 family proteins represents an exciting therapeutic opportunity. A combination of nuclear magnetic resonance (NMR)-based screening and structure-based drug design has yielded the first bona fide BCL-2 homology 3 (BH3) mimetics, including the BCL-2 and BCL-X L dual antagonist navitoclax, which is the first BCL-2 family inhibitor to show efficacy in patients with cancer. Clinical experience with navitoclax prompted the generation of the highly selective BCL-2 inhibitor venetoclax, which is now approved in the United States for the treatment of patients with chronic lymphocytic leukaemia with 17p deletion who have received at least one prior therapy. Recent advances have also been made in the development of potent and selective inhibitors of BCL-X L and myeloid cell leukaemia 1 (MCL1), which are additional BCL-2 family members with established anti-apoptotic roles in cancer. Here we review the latest progress in direct and selective targeting of BCL-2 family proteins for cancer therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Conversely, the BCL2 inhibitor venetoclax is currently available for the treatment of CLL patients who fail to obtain clinical benefit from conventional therapies [1046], and several other molecules with a similar mechanism of action are currently in clinical development [118] (source https://clinicaltrials.gov/).”
From Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. (2018) · cites this paper as [1046]
In the citing paper
“The use of Bcl-xl inhibitors as senolytics is largely limited by their on-target and dose-limiting platelet toxicity.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Bcl-xl inhibition with ABT263 and other small molecular inhibitors induces platelet apoptosis and results in severe thrombocytopenia, which prevents the use of ABT263 and other Bcl-xl specific inhibitors in the clinic—even for cancer patients—because platelets solely depend on Bcl-xl for survival24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“ABT263 (also known as navitoclax), a Bcl-2 and Bcl-xl dual inhibitor23,24, is one of the most potent and broad-spectrum senolytic agents identified to date16–18.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Because both SCs and platelets, but not NCs, are primarily dependent on Bcl-xl for survival16–18,24–27 (Supplementary Fig. 1h), we evaluated the effects of PZ compared with ABT263 on the viability of WI38 NCs (Fig. 1g, left panel), IR-SCs (Fig. 1g, middle panel), and platelets (Fig. 1g, right panel).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“As reported, ABT263 was highly toxic to both WI38 IR-SCs (Fig. 1g, middle panel) and platelets16–18,24–27 (Fig. 1g, right panel; Supplementary Fig. 2).”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“Therefore, PZ can selectively induce apoptosis in SCs, but not platelets, which are dependent on Bcl-xl for survival while having minimal toxicity to NCs that are less sensitive to Bcl-xl inhibition than SCs16–18,24–27.”
From Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity (2020) · cites this paper as [24]
In the citing paper
“the BCL2 inhibitor venetoclax has been approved by regulatory agencies for use in patients with CLL or small lymphocytic lymphoma (SLL) (Ashkenazi et al., 2017)”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Ashkenazi et al., 2017
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics
Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972) · British Journal of Cancer · doi:10.1038/bjc.1972.33 · Cited by 15,673
Death Receptors: Signaling and Modulation
Ashkenazi, A., & Dixit, V. M. (1998) · Science · doi:10.1126/science.281.5381.1305 · Cited by 5,866
Self-citationDanial, N. N., & Korsmeyer, S. J. (2004) · Cell · doi:10.1016/s0092-8674(04)00046-7 · Cited by 4,651
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells
Vaux, D., Cory, S., & Adams, J. (1988) · Nature · doi:10.1038/335440a0 · Cited by 3,355
Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy
Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Self-citationDiscovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930
Tsujimoto, Y., Finger, L. R., Yunis, J. J., Nowell̀, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6093263 · Cited by 1,769
Chipuk, J. E., Moldoveanu, T., Llambi, F., Parsons, M. J., & Green, D. R. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.01.025 · Cited by 1,476
Structure of Bcl-x L -Bak Peptide Complex: Recognition Between Regulators of Apoptosis
Sattler, M., Liang, H., Nettesheim, D., Meadows, R. P., Harlan, J. E., Eberstadt, M., Yoon, H. S., Shuker, S. B., Chang, B. S., Minn, A. J., et al. (1997) · Science · doi:10.1126/science.275.5302.983 · Cited by 1,476
Overview of cell death signaling pathways
Jin, Z., & El‐Deiry, W. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.2.1508 · Cited by 1,345
van Delft, M. F., Wei, A. H., Mason, K. D., Vandenberg, C. J., Chen, L., Czabotar, P. E., Willis, S. N., Scott, C. L., Day, C. L., Cory, S., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.027 · Cited by 1,271
McDonnell, T. J., Deane, N., Platt, F. M., Nunez, G., Jaeger, U., McKearn, J. P., & Korsmeyer, S. J. (1989) · Cell · doi:10.1016/0092-8674(89)90174-8 · Cited by 1,213
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Konopleva, M. Y., Contractor, R., Tsao, T., Samudio, I. J., Ruvolo, P. P., Kitada, S., Deng, X., Zhai, D., Shi, Y.-X., Sneed, T. B., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.006 · Cited by 1,043
Bcl-2 Inhibitors: Targeting Mitochondrial Apoptotic Pathways in Cancer Therapy
Kang, M. H., & Reynolds, C. P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0144 · Cited by 1,038
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Wilson, W. H., O'Connor, O. A., Czuczman, M. S., LaCasce, A. S., Gerecitano, J. F., Leonard, J. P., Tulpule, A., Dunleavy, K., Xiong, H., Chiu, Y.-L., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70261-8 · Cited by 876
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855
Stilgenbauer, S., Eichhorst, B. F., Schetelig, J., Coutre, S. E., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C., Roberts, A. W., Jurczak, W. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 809
Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7
Wertz, I. E., Kusam, S., Lam, C., Okamoto, T., Sandoval, W. N., Anderson, D. J., Helgason, E., Ernst, J. A., Eby, M., Liu, J., et al. (2011) · Nature · doi:10.1038/nature09779 · Cited by 801
Self-citationTsujimoto, Y., Yunis, J. J., Onorato-Showe, L., Erikson, J., Nowell̀, P. C., & Croce, C. M. (1984) · Science · doi:10.1126/science.6610211 · Cited by 650
BCL-2 family antagonists for cancer therapy
Lessène, G., Czabotar, P. E., & Colman, P. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2658 · Cited by 639
Gandhi, L., Camidge, D. R., Ribeiro de Oliveira, M., Bonomi, P., Gandara, D., Khaira, D., Hann, C. L., McKeegan, E. M., Litvinovich, E., Hemken, P. M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6208 · Cited by 603
Bedikian, A. Y., Millward, M. J., Pehamberger, H., Conry, R. M., Gore, M. E., Trefzer, U., Pavlick, A. C., DeConti, R. C., Hersh, E. M., Hersey, P., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0483 · Cited by 600
Leverson, J. D., Phillips, D. C., Mitten, M. J., Boghaert, E. R., Diaz, D., Tahir, S. K., Belmont, L. D., Nimmer, P., Xiao, Y., Ma, X. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4642 · Cited by 541
Self-citationLeverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440
Self-citationDerenne, S., Monia, B. P., Dean, N. M., Taylor, J. K., Rapp, M.-J., Harousseau, J., Bataille, R., & Amiot, M. (2002) · Blood · doi:10.1182/blood.v100.1.194 · Cited by 429
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemiaPreprint
Glaser, S. P., Lee, E. F., Trounson, E., Bouillet, P., Wei, A. H., Fairlie, W. D., Izon, D. J., Zuber, J. A., Rappaport, A., Herold, M. J., et al. (2012) · Genes & Development · doi:10.1101/gad.182980.111 · Cited by 427
The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer
Stewart, M. L., Fire, E., Keating, A. E., & Walensky, L. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.391 · Cited by 418
Expression of bcl-xL can confer a multidrug resistance phenotype
Minn, A., Rudin, C., Boise, L., & Thompson, C. (1995) · Blood · doi:10.1182/blood.v86.5.1903.bloodjournal8651903 · Cited by 415
An informatics approach identifying markers of chemosensitivity in human cancer cell lines.
Amundson, S. A., Myers, T. G., Scudiero, D. A., Kitada, S., Reed, J. C., & Fornace, A. J. (2000) · PubMed · Cited by 399
BH3-only proteins: Orchestrators of apoptosis
Shamas‐Din, A., Brahmbhatt, H., Leber, B. F., & Andrews, D. W. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.11.024 · Cited by 394
Structure-guided design of a selective BCL-XL inhibitor
Lessène, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 393
Self-citationMyeloid cell factor–1 is a critical survival factor for multiple myeloma
Zhang, B., Gojo, I., & Fenton, R. G. (2002) · Blood · doi:10.1182/blood.v99.6.1885 · Cited by 372
O'Neill, K. L., Huang, K., Zhang, J., Chen, Y., & Luo, X. (2016) · Genes & Development · doi:10.1101/gad.276725.115 · Cited by 323
Discovery of a Potent and Selective BCL-X L Inhibitor with in Vivo Activity
Tao, Z., Hasvold, L. A., Wang, L., Wang, X., Petros, A. M., Park, C. H., Boghaert, E. R., Catron, N. D., Chen, J., Colman, P. M., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5001867 · Cited by 311
Self-citationTahir, S. K., Yang, X., Anderson, M. G., Morgan-Lappe, S. E., Sarthy, A. V., Chen, J., Warner, R. B., Ng, S., Fesik, S. W., Elmore, S. W., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2203 · Cited by 308
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B., Ding, H., Joseph, M. K., Kunzer, A. R., Martineau, D., McClellan, W. J., Mitten, M. J., Ng, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 306
Huang, J. Z., Sanger, W. G., Greiner, T. C., Staudt, L. M., Weisenburger, D. D., Pickering, D. L., Lynch, J. C., Armitage, J. O., Warnke, R. A., Alizadeh, A. A., et al. (2002) · Blood · doi:10.1182/blood.v99.7.2285 · Cited by 287
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Vaillant, F., Mérino, D., Lee, L., Breslin, K. A., Pal, B., Ritchie, M. E., Smyth, G. K., Christie, M., Phillipson, L. J., Burns, C. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.002 · Cited by 275
Delving deeper: MCL-1's contributions to normal and cancer biology
Perciavalle, R. M., & Opferman, J. T. (2012) · Trends in Cell Biology · doi:10.1016/j.tcb.2012.08.011 · Cited by 233
Song, L., Coppola, D., Livingston, S., Cress, W. D., & Haura, E. B. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.3.1496 · Cited by 217
Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models
Shoemaker, A. R., Mitten, M. J., Adickes, J., Ackler, S., Refici, M. L., Ferguson, D. C., Oleksijew, A., O'Connor, J. M., Wang, B., Frost, D. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4622 · Cited by 209
A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo
Abulwerdi, F. A., Liao, C., Liu, M., Azmi, A. S., Aboukameel, A., Mady, A. S. A., Gulappa, T., Cierpicki, T., Owens, S. R., Zhang, T., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0767 · Cited by 196
Kipps, T. J., Eradat, H. A., Grosicki, S., Catalano, J. V., Cosolo, W., Dyagil, I., Yalamanchili, S., Chai, A., Sahasranaman, S., Punnoose, E. A., et al. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1030638 · Cited by 196
Small molecule Mcl-1 inhibitors for the treatment of cancer
Belmar, J., & Fesik, S. W. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.08.003 · Cited by 181
Lee, E. F., Czabotar, P. E., van Delft, M. F., Michalak, E. M., Boyle, M. J., Willis, S. N., Puthalakath, H., Bouillet, P., Colman, P. M., Huang, D. C. S., et al. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708096 · Cited by 168
Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53Preprint
Kelly, G. L., Grabow, S., Glaser, S. P., Fitzsimmons, L., Aubrey, B. J., Okamoto, T., Valente, L. J., Robati, M., Tai, L., Fairlie, W. D., et al. (2014) · Genes & Development · doi:10.1101/gad.232009.113 · Cited by 165
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines
Zhang, H., Guttikonda, S. R., Roberts, L., Uziel, T., Semizarov, D., Elmore, S. W., Leverson, J. D., & Lam, L. T. (2010) · Oncogene · doi:10.1038/onc.2010.559 · Cited by 164
Self-citationStructure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity
Bruncko, M., Wang, L., Sheppard, G. S., Phillips, D. C., Tahir, S. K., Xue, J., Erickson, S., Fidanze, S., Fry, E., Hasvold, L., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501258m · Cited by 164
Self-citationDonato, J., Campigotto, F., Uhlmann, E. J., Coletti, E., Neuberg, D. S., Weber, G. M., & Zwicker, J. I. (2015) · Blood · doi:10.1182/blood-2015-02-626788 · Cited by 160
Dysregulation of apoptosis genes in hematopoietic malignancies
Kitada, S., Pedersen, I. M., Schimmer, A. D., & Reed, J. C. (2002) · Oncogene · doi:10.1038/sj.onc.1205327 · Cited by 159
Chen, J., Jin, S. S., Abraham, V., Huang, X., Liu, B. A., Mitten, M. J., Nimmer, P. M., Lin, X., Smith, M. L., Shen, Y., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0415 · Cited by 158
Self-citationPelz, N. F., Bian, Z., Zhao, B., Shaw, S., Tarr, J. C., Belmar, J., Gregg, C., Camper, D. V., Goodwin, C. M., Arnold, A. L., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01660 · Cited by 158
Rational Design of Proteolytically Stable, Cell-Permeable Peptide-Based Selective Mcl-1 Inhibitors
Muppidi, A., Doi, K., Edwardraja, S., Drake, E. J., Gulick, A. M., Wang, H.-G., & Lin, Q. (2012) · Journal of the American Chemical Society · doi:10.1021/ja306864v · Cited by 156
Wei, S., Dong, K., Fang, L., Wang, X., Li, B., Shen, J., Zhang, Q., Wang, R., & Zhang, H. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0697-7 · Cited by 150
Ackler, S., Mitten, M. J., Foster, K., Oleksijew, A., Refici, M. L., Tahir, S. K., Yu, X. H., Tse, C., Frost, D. J., Fesik, S. W., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1232-1 · Cited by 125
Tetrahydroisoquinoline amide substituted phenyl pyrazoles as selective Bcl-2 inhibitors
Porter, J. R., Payne, A., de Candole, B., Ford, D., Hutchinson, B., Trevitt, G. P., Turner, J., Edwards, C., Watkins, C., Whitcombe, I. W. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.113 · Cited by 123
Cao, X. X., Mohuiddin, I., Ece, F., McConkey, D. J., & Smythe, W. R. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.25.5.4539 · Cited by 123
Kristen, A. V., Giannitsis, E., Lehrke, S., Hegenbart, U., Konstandin, M., Lindenmaier, D., Merkle, C., Hardt, S. E., Schnabel, P. A., Röcken, C., et al. (2010) · Blood · doi:10.1182/blood-2010-02-267708 · Cited by 114
MAPK signaling cascades mediate distinct glucocorticoid resistance mechanisms in pediatric leukemia.
Jones, C. L., Gearheart, C. M., Fosmire, S., Delgado-Martín, C., Evensen, N. A., Bride, K. L., Waanders, A., Pais, F. M., Wang, J.-H., Bhatla, T., et al. (2015) · Blood · doi:10.1182/blood-2015-04-639138 · Cited by 110
Burke, J. P., Bian, Z., Shaw, S., Zhao, B., Goodwin, C. M., Belmar, J., Browning, C. F., Vigil, D., Friberg, A., Camper, D. V., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501984f · Cited by 105
Evaluation and critical assessment of putative MCL-1 inhibitors
Varadarajan, S., Vogler, M., Butterworth, M., Dinsdale, D. D., Walensky, L. D., & Cohen, G. M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.79 · Cited by 101
Conformational Changes in Bcl-2 Pro-survival Proteins Determine Their Capacity to Bind Ligands
Lee, E. F., Czabotar, P. E., Yang, H. J., Sleebs, B. E., Lessène, G., Colman, P. M., Smith, B. J., & Fairlie, W. D. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.040725 · Cited by 87
Bai, L., Chen, J., McEachern, D., Liu, L., Zhou, H., Aguilar, A., & Wang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099404 · Cited by 83
Gerecitano, J. F., Roberts, A. W., Seymour, J. F., Wierda, W. G., Kahl, B. S., Pagel, J. M., Puvvada, S. D., Kipps, T. J., Anderson, M. A., Dunbar, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.254.254 · Cited by 74
Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML)
Bose, P., & Grant, S. (2013) · Leukemia Research Reports · doi:10.1016/j.lrr.2012.11.006 · Cited by 72
Sleebs, B. E., Czabotar, P. E., Fairbrother, W. J., Fairlie, W. D., Flygare, J. A., Huang, D. C. S., Kersten, W. J. A., Koehler, M. F. T., Lessène, G., Lowes, K. N., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101596e · Cited by 72
Self-citationSmith, B. J., Lee, E. F., Checco, J. W., Evangelista, M., Gellman, S. H., & Fairlie, W. D. (2013) · ChemBioChem · doi:10.1002/cbic.201300351 · Cited by 65
Akagi, H., Higuchi, H., Sumimoto, H., Igarashi, T., Kabashima, A., Mizuguchi, H., Izumiya, M., Sakai, G., Adachi, M., Funakoshi, S., et al. (2012) · Gastric Cancer · doi:10.1007/s10120-012-0153-6 · Cited by 63
Dinardo, C. D., Pollyea, D. A., Pratz, K. W., Thirman, M. J., Letai, A. G., Frattini, M. G., Jonas, B. A., Leverson, J. D., Zhu, M., Dunbar, M., et al. (2015) · Blood · doi:10.1182/blood.v126.23.327.327 · Cited by 62
Self-citationRichard, D. J., Lena, R. J., Bannister, T. D., Blake, N., Pierceall, W. E., Carlson, N. E., Keller, C. E., Koenig, M., He, Y., Minond, D., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.08.017 · Cited by 60
Mito-priming as a method to engineer Bcl-2 addiction
Lopez, J., Bessou, M., Riley, J. S., Giampazolias, E., Todt, F., Rochegüe, T., Oberst, A., Green, D. R., Edlich, F., Ichim, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms10538 · Cited by 58
A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML)
Konopleva, M. Y., Pollyea, D. A., Potluri, J., Chyla, B., Busman, T. A., McKeegan, E. M., Salem, A. H., Zhu, M., Ricker, J. L., Blum, W. G., et al. (2014) · Blood · doi:10.1182/blood.v124.21.118.118 · Cited by 57
Self-citationZhang, H., Xue, J., Hessler, P., Tahir, S. K., Chen, J., Jin, S. S., Souers, A. J., Leverson, J. D., & Lam, L. T. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0397-y · Cited by 53
Self-citationMa, S., Brander, D. M., Seymour, J. F., Kipps, T. J., Barrientos, J. C., Davids, M. S., Anderson, M. A., Choi, M. Y., Tam, C. S. L., Mason-Bright, T., et al. (2015) · Blood · doi:10.1182/blood.v126.23.830.830 · Cited by 51
Rajan, S. S., Choi, M., Baek, K., & Yoon, H. S. (2015) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24816 · Cited by 50
Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
Némati, F., de Montrion, C., Lang, G., Kraus‐Berthier, L., Carita, G., Sastre‐Garau, X., Berniard, A., Vallerand, D., Geneste, O., de Plater, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080836 · Cited by 49
Getting a handle on hereditary CEBPA mutations
Dinardo, C. D. (2015) · Blood · doi:10.1182/blood-2015-07-657908 · Cited by 46
Moreau, J. M., Berger, A., Nelles, M. E., Mielnik, M., Furlonger, C. L., Cen, S. Y., Besla, R., Robbins, C. S., & Paige, C. J. (2015) · Blood · doi:10.1182/blood-2015-03-635805 · Cited by 45
Molecular Basis of Bcl-XL-p53 Interaction: Insights from Molecular Dynamics Simulations
Bharatham, N., Chi, S., & Yoon, H. S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026014 · Cited by 40
Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL
Koehler, M. F. T., Bergeron, P., Choo, E. F., Lau, K., Ndubaku, C. O., Dudley, D. A., Gibbons, P., Sleebs, B. E., Rye, C. S., Nikolakopoulos, G., et al. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500030p · Cited by 38
Self-citationDefining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
Koss, B. S., Ryan, J. A., Budhraja, A., Szarama, K. B., Yang, X., Bathina, M., Cardone, M. H., Nikolovska‐Coleska, Z., Letai, A. G., & Opferman, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.7204 · Cited by 36
Jones, J. A., Mato, A. R., Coutre, S. E., Wierda, W. G., Choi, M. Y., Davids, M. S., Lamanna, N., Barr, P. M., Burns, K. M., Montalvo, N. P., et al. (2015) · Blood · doi:10.1182/blood.v126.23.715.715 · Cited by 36
de Vos, S., Swinnen, L. J., Kozloff, M., Wang, D., Reid, E. G., Nastoupil, L. J., Fowler, N. H., Cordero, J., D'Amico, D., Diehl, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.255.255 · Cited by 35
Flinn, I. W., Brunvand, M. W., Choi, M. Y., Dyer, M. J. S., Gribben, J. G., Hillmen, P., Jones, J. A., Li, Y., Mobasher, M., Vosganian, G. S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.494.494 · Cited by 31
Clearance of systemic hematologic tumors by venetoclax (Abt‐199) and navitoclax
Ackler, S., Oleksijew, A., Chen, J., Chyla, B., Clarin, J. D., Foster, K., McGonigal, T. P., Mishra, S., Schlessinger, S., Smith, M. L., et al. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.178 · Cited by 27
Self-citationFlinn, I. W., Brunvand, M. W., Dyer, M. J. S., Hillman, P., Jones, J. A., Lymp, J. F., Elhamy, M., Vosganian, G. S., Huang, J. Q., & Kipps, T. J. (2014) · Blood · doi:10.1182/blood.v124.21.4687.4687 · Cited by 26
Kipps, T. J., Swinnen, L. J., Wierda, W. G., Jones, J. A., Coutre, S. E., Smith, M. R., Yang, J., Cui, Y., Busman, T. A., Enschede, S. H., et al. (2011) · Blood · doi:10.1182/blood.v118.21.3904.3904 · Cited by 26
Puglisi, M., van Doorn, L., Blanco-Codesido, M., Jonge, M. J. D., Moran, K., Yang, J., Busman, T. A., Franklin, C., Mabry, M., Krivoshik, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.2518 · Cited by 24
Moreau, P., Chanan-Khan, A. A., Roberts, A. W., Agarwal, A. B., Facon, T. T. F., Kumar, S. K., Touzeau, C., Darden, D. E., Morris, L. J., Ross, J. A., et al. (2015) · Blood · doi:10.1182/blood.v126.23.3038.3038 · Cited by 20
Self-citationKumar, S. K., Vij, R., Kaufman, J. L., Mikhael, J. R., Facon, T. T. F., Pegourié, B., Benboubker, L., Moreau, P., Amiot, M., Alzate, S., et al. (2015) · Blood · doi:10.1182/blood.v126.23.4219.4219 · Cited by 16
Self-citationSalles, G., Boyd, T. E., Morschhauser, F., Wendtner, C., Hallek, M. J., Eichhorst, B. F., Kozloff, M. F., Cartron, G., Li, Y., Hilger, J. D., et al. (2015) · Blood · doi:10.1182/blood.v126.23.829.829 · Cited by 11
Game, set, match for factor VIII mismatch?
Miller, C. H. (2015) · Blood · doi:10.1182/blood-2015-02-625574 · Cited by 6
A Dual Bcl-2/xL Inhibitor Induces Tumor Cell Apoptosis in a Hematopoietic Xenograft Model
Adam, A., Byth, K. F., Secrist, P., Schuller, A. G., Reimer, C., Lawson, D., Macintyre, T., & Powell, F. (2014) · Blood · doi:10.1182/blood.v124.21.5304.5304 · Cited by 5
Sensintaffar, J., Arnold, A. L., Goodwin, C. M., Hogdal, L. J., Shaw, S., Tarr, J. C., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3727 · Cited by 1
Research works printed but not linked: 1
- Seymour, J. F. et al. Reduction of tumor lysis syndrome (TLS) risk in chronic lymphocytic leukemia (CLL) patients treated with ABT-199 (GDC-0199): results of modifications to dosing schedule and TLS prophylaxis [abstract P868]. Haematologica 99 (Suppl. 1), 321 (2014).
Cited by
Sorted by citations
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,813
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2017) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,323
NINJ1 mediates plasma membrane rupture during lytic cell death
Kayagaki, N., Kornfeld, O. S., Lee, B. L., Stowe, I. B., O’Rourke, K., Li, Q., Sandoval, W., Yan, D., Kang, J., Xu, M., et al. (2021) · Nature · doi:10.1038/s41586-021-03218-7 · Cited by 857
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Khan, S., Zhang, X., Lv, D., Zhang, Q., He, Y., Zhang, P., Liu, X., Thummuri, D., Yuan, Y., Wiegand, J. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0668-z · Cited by 688
Metadata
- Authors
- Ashkenazi, A., Fairbrother, W. J., Leverson, J. D., & Souers, A. J.
- Affiliations
- Genentech (US)
- AbbVie (United States) (US)
- Corresponding author
- Ashkenazi, Avi
- Venue
- Nature Reviews Drug Discovery
- Published
- 2017-02-17
- Volume
- 16
- Issue
- 4
- Pages
- 273-284
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2589060305
- Cited by
- 903
- References
- 105
- Citations by year
- 2026: 49 · 2025: 87 · 2024: 99 · 2023: 90 · 2022: 94 · 2021: 120 · 2020: 116 · 2019: 93 · 2018: 100 · 2017: 51
- FWCI
- 9.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- Bcl-2 family proteins, apoptosis, BH3 mimetics, BCL-2 inhibitor, venetoclax, navitoclax, Bcl-xL, Mcl-1, small molecule inhibitors, structure-based drug design, NMR-based screening, apoptosis evasion, chronic lymphocytic leukemia, 17p deletion, cancer therapy
- MeSH terms
- Antineoplastic Agents, Humans, Neoplasms, Molecular Structure, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Protein Interaction Domains and Motifs, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
